Agenus Inc. (NASDAQ:AGEN) Receives $10.00 Average Target Price from Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have received a consensus rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

AGEN has been the topic of a number of analyst reports. B. Riley lowered their target price on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, HC Wainwright lowered their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, November 12th.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $3.49 on Thursday. The business’s fifty day moving average price is $4.30 and its two-hundred day moving average price is $8.20. The stock has a market cap of $81.88 million, a PE ratio of -0.31 and a beta of 1.39. Agenus has a one year low of $2.50 and a one year high of $19.69.

Institutional Investors Weigh In On Agenus

Hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd acquired a new stake in shares of Agenus during the second quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Agenus in the 2nd quarter worth $106,000. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 3rd quarter worth $55,000. HighTower Advisors LLC raised its position in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares during the period. Finally, Blair William & Co. IL purchased a new position in shares of Agenus in the 2nd quarter worth $441,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.